Here, we developed a non-invasive, isothermal, sensitive, and fast assay, termed as exosome-hybridization chain reaction (ExoHCR) for PD-L1 level profiling on tumor cell exosomes, with the long-term goal of ICB-related therapeutic response prediction and patient stratification (Fig. 1). This evidence concerns the gene CD274 and neoplasm.